胸腺五肽联合2HRZE/4HR方案治疗初治肺结核的疗效观察

Effect of Thymopentin Combined with 2HRZE/4HR in the Treatment of Primary Pulmonary Tuberculosis

目的探讨胸腺五肽联合2HRZE/4HR(H-异烟肼,R-利福平,Z-吡嗪酰胺,E-乙胺丁醇)方案对初治肺结核患者的临床疗效。方法回顾性分析湖南省胸科医院2018年2月—2019年3月期间收治的初治肺结核(84例)患者的临床资料,视其药物治疗方案的不同给予分组,分别为对照组(42例)与观察组(42例)。两组均连续治疗6个月,观察两组病灶吸收情况、治疗后免疫球蛋白水平及不良反应情况。结果观察组治疗6个月后病灶吸收情况优于对照组(P<0.05);治疗后,观察组免疫球蛋白A(Immunoglobulin A,IgA)、免疫球蛋白M(Immunoglobulin M,IgM)、免疫球蛋白G (Immunoglobulin G,IgG)水平均低于对照组,差异有统计学意义(P<0.05);两组不良反应比较,差异无统计学意义(P>0.05)。结论胸腺五肽联合2HRZE/4HR方案治疗初治肺结核患者,可提高临床疗效,促进病灶吸收,改善机体免疫功能,且安全性高。

Objective To investigate the clinical effect of thymopentin combined with 2HRZE/4 HR(H-isoniazid, R-rifampin,Z-pyrazinamide and E-ethambutol) in the treatment of primary pulmonary tuberculosis. Methods The clinical data of 84 patients with primary pulmonary tuberculosis admitted to the hospital from February, 2018 to March, 2019 were analyzed retrospectively.According to different drug treatment schemes, they were divided into control group(42 cases) and observation group(42 cases).The absorption of focus, the level of immunoglobulin and the adverse reactions were observed. Results The absorption of focus in the observation group was better than that in the control group after 6 months of treatment, and the difference was statistically significant(P<0.05). After treatment, the levels of immunoglobulin A(IGA), immunoglobulin M(IgM)and immunoglobulin G(IgG)in the observation group were lower than those in the control group, and the difference was statistically significant(P<0.05). There was no significant difference in adverse effect in two groups(P>0.05). Conclusion Thymopentin combined with 2 HRZE/4 HR can improve the clinical effect, absorption of the focus and immune function. It is safe.